Evaluation of the effect of Ningbitai capsules combined with surgery in the treatment of chronic prostatitis complicated with benign prostatic hyperplasia

doi:10.3760/cma.j.issn.1007-1245.2023.23.019

Abstract

Abstract:

Objective　To analyze the application value of Ningbitai capsules combined with surgery in the treatment of chronic prostatitis (CP) with benign prostatic hyperplasia (BPH). Methods　The clinical data of 76 patients with CP complicated with BPH admitted to Liaocheng Third People's Hospital from June 2019 to June 2022 were retrospectively collected, and they were divided into two groups according to different treatment methods, with 38 cases in each group. The observation group was (61.58±6.44) years old, and the control group was (62.31±7.28) years old. All patients underwent transurethral plasmakinetic resection of prostate (PKRP). The control group was given routine treatment, and the observation group was given Ningbitai capsules on the basis of the control group. The medication started 2 weeks before surgery and continued till 2 weeks after surgery, for a total of 1 month.The operation-related indexes, levels of inflammatory markers [macrophage inflammatory protein-1α (MIP-1α), vascular cell adhesion molecule-1 (VCAM-1), and interleukin-6 (IL-6)] before treatment, 1 d before surgery, and 2 weeks after surgery, and urodynamic indexes [maximum urinary flow rate (Qmax), residual urine volume (PVR), and bladder stability], National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) scores, and International Prostatitis Symptom Scale (IPSS) scores before treatment, 1 day before surgery, and 3 months after surgery were compared between the two groups. Independent sample t test and paired t test were used. Results　The operation time, hospital stay, and intraoperative blood loss were (51.49±12.44) min, (5.19±0.98) days, and (79.58±8.13) ml in the observation group, and (68.73±14.35) min, (6.08±1.22) days, (98.55±10.24) ml in the control group, respectively, with statistically significant differences (t=5.596, 3.506, and 8.944, all P<0.01). Serum MIP-1α, VCAM-1, and IL-6 levels in the observation group were (14.95±2.18) µg/L, (72.58±8.51) ng/L, and (185.73±32.62) ng/L 1 day before surgery, those were (6.51±1.38) µg/L, (40.28±8.75) ng/L, and (119.24±35.58) ng/L 2 weeks after surgery, and the results in the control group were (16.83±2.27) µg/L, (81.44±8.22) ng/L, and (215.37±31.11) ng/L 1 day before surgery and (8.11±1.44) µg/L, (54.56±7.93) ng/L, and (153.15±39.48) ng/L 2 weeks after surgery, with statistically significant differences (t=3.682, 4.616, 4.053, 4.945, 7.454, and 3.993, all P<0.001). The Qmax, bladder stability, and PVR in the observation group 3 months after surgery were (12.39±2.47) ml/s, (174.65±15.32) ml, and (44.66±15.26) ml, those in the control group were (9.25±2.31) ml/s, (154.51±16.83) ml, and (62.79±14.93) ml, with statistically significant differences (t=5.724, 5.455, and 5.235, all P<0.001). The NIH-CPSI score of the observation group was (17.17±2.11) 1 day before surgery and (7.84±1.08) points 3 months after surgery, while those of the control group were (19.16±2.15) and (10.29±1.25) points (t=4.072 and 9.143, both P<0.001). The IPSS score of the observation group was lower than that of the control group 3 months after surgery [(8.17±1.43) points vs. (11.22±1.68) points] (t=8.552, P<0.001). Conclusion　Ningbitai capsules combined with PKRP in the treatment of CP with BPH can reduce the inflammatory reaction, improve the urodynamics, and helps to recover.

Key words:

Chronic prostatitis, Benign prostatic hyperplasia, Ningbitai capsules, Urodynamics, Inflammation indexes

摘要：

目的　分析宁泌泰胶囊联合手术在慢性前列腺炎合并前列腺增生患者治疗中的应用价值。方法　回顾性收集2019年6月至2022年6月聊城市第三人民医院收治的76例慢性前列腺炎合并前列腺增生患者临床资料，根据治疗方法不同分为两组，每组38例。观察组年龄（61.58±6.44）岁，对照组年龄（62.31±7.28）岁。均实施经尿道前列腺等离子电切术（PKRP），对照组给予常规治疗，观察组于对照组基础上加用宁泌泰胶囊。术前2周开始用药，并于手术后持续用药2周，共用药1个月。比较两组手术相关指标，治疗前、术前1 d及术后2周炎症指标［巨噬细胞炎性蛋白-1α（MIP-1α）、血管细胞黏附分子-1（VCAM-1）、白细胞介素-6（IL-6）］水平，治疗前、术前1 d及术后3个月尿流动力学指标［最大尿流率（Q_max）、残余尿量（PVR）、膀胱稳定性］、慢性前列腺炎症状评分表（NIH-CPSI）评分、国际前列腺症状评分表（IPSS）评分。采用独立样本t检验、配对t检验。结果　观察组手术时间、住院时间、术中出血量分别为（51.49±12.44）min、（5.19±0.98）d、（79.58±8.13）ml，对照组为（68.73±14.35）min、（6.08±1.22）d、（98.55±10.24）ml，差异均有统计学意义（t=5.596、3.506、8.944，均P<0.01）。观察组术前1 d血清MIP-1α、VCAM-1、IL-6水平分别为（14.95±2.18）µg/L、（72.58±8.51）ng/L、（185.73±32.62）ng/L，术后2周分别为（6.51±1.38）µg/L、（40.28±8.75）ng/L、（119.24±35.58）ng/L；对照组术前1 d为（16.83±2.27）µg/L、（81.44±8.22）ng/L、（215.37±31.11）ng/L，术后2周为（8.11±1.44）µg/L、（54.56±7.93）ng/L、（153.15±39.48）ng/L，差异均有统计学意义（t=3.682、4.616、4.053、4.945、7.454、3.993，均P<0.001）。观察组术后3个月Q_max、膀胱稳定性、PVR分别为（12.39±2.47）ml/s、（174.65±15.32）ml、（44.66±15.26）ml，对照组为（9.25±2.31）ml/s、（154.51±16.83）ml、（62.79±14.93）ml，差异均有统计学意义（t=5.724、5.455、5.235，均P<0.001）。观察组术前1 d、术后3个月NIH-CPSI评分分别为（17.17±2.11）分、（7.84±1.08）分，对照组为（19.16±2.15）分、（10.29±1.25）分（t=4.072、9.143，均P<0.001）。观察组术后3个月IPSS评分低于对照组［（8.17±1.43）分比（11.22±1.68）分］（t=8.552，P<0.001）。结论　宁泌泰胶囊联合PKRP治疗慢性前列腺炎合并前列腺增生，能减轻炎症反应，改善尿流动力学，有助于病情恢复。

关键词:

慢性前列腺炎, 前列腺增生, 宁泌泰胶囊, 尿流动力学, 炎症指标

Zhao Zongyong, Ren Zhishang, Xu Long, Diao Tongxiang.

Evaluation of the effect of Ningbitai capsules combined with surgery in the treatment of chronic prostatitis complicated with benign prostatic hyperplasia [J]. International Medicine and Health Guidance News, 2023, 29(23): 3407-3411.

赵宗勇任之尚徐龙刁统祥.

宁泌泰胶囊联合手术治疗慢性前列腺炎合并前列腺增生的效果评价 [J]. 国际医药卫生导报, 2023, 29(23): 3407-3411.

References

[1] 吴永超,张锐. 前列腺增生症合并慢性前列腺炎的手术治疗价值分析[J]. 航空航天医学杂志,2022,33(8):945-947. DOI:10.3969/j.issn.2095-1434.2022.08.017.
[2] 罗玉红,黄蓉蓉,龙颖,等. 前列腺增生症患者主观幸福感现状及影响因素分析[J]. 中国男科学杂志,2022,36(3):38-43,49. DOI:10.3969/j.issn.1008-0848.2022.03.006.
[3] Cao Q, Wu Y, Guan W, et al. Diagnosis of chronic prostatitis by noninvasive methods in elderly patients with benign prostatic hyperplasia in China[J].Andrologia,2021,53(6):e14055. DOI:10.1111/and.14055.
[4] 周硕明,朱自强. 炎症小体与前列腺炎及代谢综合征所致良性前列腺增生关系的研究进展[J]. 临床泌尿外科杂志,2020,35(9):744-747. DOI:10.13201/j.issn.1001-1420. 2020.09.015.
[5] 宋晓琳,王文祯. 经尿道前列腺等离子电切术与前列腺汽化电切术治疗前列腺增生合并慢性前列腺炎的疗效比较[J]. 医学临床研究,2021,38(10):1512-1514,1518. DOI:10.3969/j.issn.1671-7171.2021.10.020.
[6] 白强民,张春和,秦华萍,等. 前列腺增生症合并慢性前列腺炎中医体质及证候分布规律探讨[J]. 云南中医学院学报,2019,42(5):23-27. DOI:10.19288/j.cnki.issn.1000-2723. 2019.05.005.
[7] 王浩浩,王世桢,赵琦,等. 李曰庆教授运用温清二法治疗慢性前列腺炎的临床经验[J]. 现代中医临床,2022,29(4):37-40. DOI:10.3969/j.issn.2095-6606.2022.04.007.
[8] 李其信,傅伟,游旭军,等. 肾虚血瘀型良性前列腺增生患者勃起功能及生活质量的临床研究[J]. 临床泌尿外科杂志,2020,35(2):94-98. DOI:10.13201/j.issn.1001-1420.2020. 02.002.
[9] 王东珊,王权胜.从"少腹里急"应用大黄虫丸论治前列腺炎[J].中国中医基础医学杂志,2019,25(6):856-857,863.DOI: 10.19945/j.cnki.issn.1006-3250.2019.06.048.
[10] 那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南手册[M]. 北京:人民卫生出版社, 2014.
[11] 李健,祁娜. 慢性前列腺炎/慢性盆腔疼痛综合征患者的心理弹性及其影响因素分析[J]. 中国性科学,2022,31(12):60-63. DOI:10.3969/j.issn.1672-1993.2022.12.015.
[12] Hopland-Nechita FV, Andersen JR, Beisland C. IPSS "bother question" score predicts health-related quality of life better than total IPSS score[J]. World J Urol, 2022,40(3): 765-772. DOI:10.1007/s00345-021-03911-2.
[13] 杜国伟,熊晶,陈赵,等. 前列腺增生合并组织学前列腺炎患者的临床特征及术后并发症分析[J]. 现代泌尿外科杂志,2020,25(7):596-600. DOI:10.3969/j.issn.1009-8291. 2020.07.006.
[14] 崔占武. 三种手术方式治疗良性前列腺增生的效果比较[J]. 国际医药卫生导报,2020,26(23):3663-3666. DOI:10.3760/cma.j.issn.1007-1245.2020.23.033.
[15] 黄天骄,郑入文. 关于慢性前列腺炎中医病名的两点商榷[J]. 中医学报,2020,35(5):980-982. DOI:10.16368/j.issn.1674-8999.2020.05.221.
[16] 赵晰,王耀光,李蔓. 王耀光针药合用辨治癃闭经验举要[J]. 辽宁中医杂志,2019,46(1):27-29. DOI:10.13192/j.issn.1000-1719.2019.01.008.
[17] 白强民.前列通窍胶囊治疗前列腺增生症合并慢性前列腺炎的临床研究[D].云南:云南中医药大学,2020.DOI:10.27460/d.cnki.gyzyc.2020.000010.
[18] 徐洪胜,李海松,王世桢,等. 李海松教授从瘀、虚论治慢性前列腺炎经验[J]. 陕西中医,2022,43(10):1445-1448. DOI:10.3969/j.issn.1000-7369.2022.10.030.
[19] 吴梦婷,史渊源,王停,等. 前列腺增生症中医治则治法、常用方药文献研究[J]. 中国实验方剂学杂志,2019,25(19):198-203. DOI:10.13422/j.cnki.syfjx.20191923.
[20] 夏庆昌,宋景艳,周悦,等. 隔药灸脐法联合宁泌泰胶囊治疗湿热下注型精液不液化:随机对照研究[J]. 中国针灸,2021,41(12):1321-1324. DOI:10.13703/j.0255-2930. 20201229-k0007.
[21] 毛可人,张波,徐仁芳. 宁泌泰胶囊联合地奥司明、左氧氟沙星对老年慢性前列腺炎患者血清及前列腺液内免疫介导因子的影响及临床疗效研究[J]. 中国免疫学杂志,2019,35(14):1755-1759. DOI:10.3969/j.issn.1000- 484X.2019.14.019.
[22] 郭战萍,任静静,王珊珊.血清MIP-1α、MCP-1水平与小儿细菌性脑膜炎病情严重程度及预后的相关性分析[J].中国病原生物学杂志,2021,16(12):1454-1457.DOI:10.13350/j.cjpb.211219.
[23] 刁建军,吴波,张姝红,等. 慢性前列腺炎患者前列腺液中WBC、SPL、Ig及趋化因子水平变化及意义[J]. 重庆医学,2022,51(10):1665-1669. DOI:10.3969/j.issn.1671-8348. 2022.10.009.
[24] 钟勇,诸发明,袁野. 癃清片联合诺氟沙星治疗慢性前列腺炎的临床研究[J]. 现代药物与临床,2019,34(8):2454-2457. DOI:10.7501/j.issn.1674-5515.2019.08.045.
[25] 王磊,洪正东. 前列泰胶囊联合左氧氟沙星治疗湿热挟瘀型慢性前列腺炎的临床观察及其对PSA、MIP-2、VCAM-1水平的影响[J]. 药物评价研究,2021,44(9):1939-1944. DOI:10.7501/j.issn.1674-6376.2021.09.019.
[26] 姬学义,李健,刘愿光,等. 血清铁蛋白、IL-6和前列腺特异性抗原联合检测在前列腺癌诊断中的应用[J]. 现代临床医学,2021,47(5):325-327,349. DOI:10.11851/j.issn.1673- 1557.2021.05.002.
[27] 田海军,徐冬,田安然,等. 血清炎症指标水平与良性前列腺增生的相关性研究[J]. 华南国防医学杂志,2020,34(1):20-22,31. DOI:10.13730/j.issn.1009-2595.2020.01.005.
[28] 张力杰,陈明,朱伟东. 良性前列腺增生患者前列腺组织及外周血Th1/Th2/Th17及相关细胞因子多参数检测的临床意义[J]. 中国免疫学杂志,2020,36(24):3030-3035. DOI:10.3969/j.issn.1000-484X.2020.24.017.
[29] 赵丰,邓楹君,陈亚洲,等. 基于"异病同治"理论的宁泌泰胶囊治疗慢性前列腺炎和良性前列腺增生症的网络药理学研究[J]. 中国男科学杂志,2022,36(2):39-47. DOI:10.3969/j.issn.1008-0848.2022.02.006.
[30] 刘喜,张佳丽,杜重伟,等. 宁泌泰胶囊治疗尿路感染对患者炎症反应水平和免疫功能的影响[J]. 临床和实验医学杂志,2021,20(7):766-770. DOI:10.3969/j.issn.1671-4695. 2021.07.028.